COCP Cocrystal Pharma Inc

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time.

Mr. Martin will be available throughout the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can to attend the conference virtually or in-person at the Lotte New York Palace Hotel. The Cocrystal Pharma presentation is posted to the Company website .

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that addresses significant unmet needs by developing innovative antiviral treatments for challenging diseases including influenza, viral gastroenteritis, COVID, and hepatitis. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

Contact:

Alliance Advisors IR

Jody Cain

310-691-7100

# # #



EN
03/09/2025

Underlying

COCPCocrystal Pharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cocrystal Pharma Inc

 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investme...

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time. Mr. Martin will be available throughout the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can to attend the conference virtually or in-person at the...

September 3, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Pro...

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and six months ended June 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. “Preparations are underway for a Phase 1...

August 14, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-...

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well toleratedCompany expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this yearLack of approved norovirus treatments or vaccines creates critical unmet medical need BOTHELL, Wash., Aug. 05, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) announces the presentation of favorable safety and tolerability data from a randomized, double-blinded, placebo-controlled...

August 5, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class ...

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being held September 7-11, 2025 in Banff, Alberta, Canada. Sam Lee, PhD, the Company’s President and co-CEO, will present “Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: M...

July 10, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Depart...

Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHSRS) being held August 4-7 in Kissimmee, Fla. Cocrystal is developing CDI-988 as a norovirus prophylaxis and treatment. Sam Lee, PhD, the Company’s President and co-CEO, will discuss Phase 1 results during the Broad-Spectrum Anti-Viral Countermeasures breakout ses...

June 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch